pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
NOVARTIS · news · pharmadog
← back to NOVARTIS
News mentioning NOVARTIS
367
stories
6h
Immutep, Molecular cut workforces
biospace
9h
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
biopharma dive
18h
Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot
fiercebiotech
1d
Dren Bio lands $350M to push rare blood cancer therapy toward market
biospace
2d
Geron’s Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bid
fiercebiotech
2d
Lilly shuffles business structure; Novartis writes off part of Avidity deal
biopharma dive
2d
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
biospace
2d
Big Pharma is ready to strike, with J&J most likely to buy: Leerink
biospace
2d
5 new drug launches that defied industry expectations
biospace
3d
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
biopharma dive
3d
Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
biospace
3d
After $1.9B impairment hit, Novartis stands by $12B bet on Avidity
endpoints
3d
Novartis considers bypassing European government payers due to MFN
endpoints
3d
Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy
fiercebiotech
3d
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
fiercebiotech
4d
Aspen, Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCs
endpoints
4d
Another autoimmune CAR-T death; Treasury zeroes in on China deals
biopharma dive
4d
STAT+: Five biotech updates to read after ESMO this weekend
stat
4d
Anthropic lays out drug R&D ambitions, risks in mammoth IPO filing
fiercebiotech
4d
STAT+: Moderna CEO on what’s next after success in cancer vaccine
stat
4d
Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy
biospace
6d
STAT+: The ESMO presentation everyone’s been waiting for
stat
7d
STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early
stat
7d
STAT+: Diabetes association says ‘threat’ preceded members’ ejections, but admits policies were unclear
stat
7d
STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
stat
7d
BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial
biospace
7d
STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
stat
7d
BMS sheds light on patient death in CAR-T trial, wants to get program back on track
fiercebiotech
7d
Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial
endpoints
7d
Roche puts numbers behind phase 3 kidney disease win amid blockbuster ambitions
fiercebiotech
← prev
page 1 of 13
next →
